局限性前列腺癌4次立体定向体部放疗的II期试验
这项II期研究纳入55例局限性前列腺癌患者,给予4次共36 Gy的立体定向体部放疗,3年生化控制率为89.8%,急性和晚期2级泌尿生殖及胃肠道毒性发生率分别为9%、11%和13%、7%,晚期3级泌尿生殖及胃肠道毒性各1例(1.8%)。作者结论认为该方案安全有效且生活质量结局良好,但毒性略重于当前标准。
要点
- 55例局限性前列腺癌患者接受4次共36 Gy的立体定向体部放疗,3年生化控制率为89.8%。
- 急性2级泌尿生殖毒性和胃肠道毒性分别见于5例(9%)和6例(11%),无3级及以上急性毒性。
- 晚期2级泌尿生殖毒性和胃肠道毒性分别见于7例(13%)和4例(7%),晚期3级各1例(1.8%)。
核心结论
- 作者结论认为,4次共36 Gy的立体定向体部放疗安全有效且生活质量结局良好,但该方案毒性略重于当前标准。
研究设计与样本
- II期研究纳入2015年至2018年间55例接受4次共36 Gy立体定向体部放疗的局限性前列腺癌患者。
- 按美国国家综合癌症网络标准分为低危4例、中危31例、高危20例,中位年龄73岁(范围54-86岁)。
- 37例(三分之二)患者接受雄激素剥夺治疗3-46个月(中位31个月),中位随访36个月(范围1-54个月)。
- 毒性评估采用放射治疗肿瘤学组和美国国家癌症研究所常见毒性标准第4版,生活质量采用扩展前列腺癌综合指数评估。
主要发现
- 全部患者完成方案治疗,6例出现生化失败,其中3例出现临床失败,1例在生化失败前出现骨转移,1例死于胃癌。
- 3年生化控制率为89.8%。
- 急性2级泌尿生殖毒性和胃肠道毒性分别见于5例(9%)和6例(11%),未观察到3级及以上急性毒性。
- 晚期2级泌尿生殖毒性和胃肠道毒性分别见于7例(13%)和4例(7%),晚期3级泌尿生殖毒性和胃肠道毒性各1例(1.8%)。
- 扩展前列腺癌综合指数评分在急性期轻度下降,并在治疗后3个月内恢复。
局限性
- 作者结论指出,该方案毒性略重于当前标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE(S): To report results from our phase II study of stereotactic body radiotherapy (SBRT) delivering 36 Gy in 4 fractions for patients with localized prostate cancer. MATERIALS/METHODS: We enrolled 55 patients treated with SBRT delivering 36 Gy in 4 fractions between 2015 to 2018. All patients were categorized as low-risk (n = 4), intermediate-risk (n = 31) or high-risk (n = 20) according to National Comprehensive Cancer Network criteria. Median age was 73 years (range 54-86 years). Two-thirds of patients (n = 37) had received androgen-deprivation therapy for 3-46 months (median, 31 months). Median duration of follow-up was 36 months (range 1-54 months). We used Radiation Therapy Oncology Group and National Cancer Institute-Common Toxicity Criteria version 4 for toxicity assessments. Quality of life (QOL) outcomes were also evaluated using the Expanded Prostate Cancer Index Composite (EPIC). RESULTS: Protocol treatments were completed for all patients. Six patients experienced biochemical failures. Among these six patients, three patients experienced clinical failure. One patient showed bone metastasis before biochemical failure. One patient died of gastric cancer. The 3-year biochemical control rate was 89.8%. Acute grade 2 genitourinary (GU) and gastrointestinal (GI) toxicities were observed in 5 patients (9%) and 6 patients (11%), respectively. No grade 3 or higher acute toxicities were observed. Late grade 2 GU and GI toxicities were observed in 7 patients (13%) and 4 patients (7%), respectively. Late grade 3 GU and GI toxicities were observed in 1 patient (1.8%) each. EPIC scores decreased slightly during the acute phase and recovered within 3 months after treatment. CONCLUSION: Our phase II study showed that SBRT delivering 36 Gy in 4 fractions was safe and effective with favorable QOL outcomes, although this regimen showed slightly more severe toxicities compared to current standards.
引用
- Kawakami S, Tsumura H, Satoh T, et al. A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer. Radiat Oncol. 2022. PMID: 35379264. doi:10.1186/s13014-022-02037-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。